Budesonide

證據等級: L5

預測適應症: 10 個

Budesonide: From Inflammatory Airway & Gut Disease to Atopic Eczema

One-Sentence Summary

Budesonide is a synthetic glucocorticoid widely used globally to manage chronic inflammatory diseases of the airways (asthma, COPD) and gastrointestinal mucosa (Crohn's disease, microscopic colitis), though it is currently not registered in Saudi Arabia. The TxGNN model predicts it may be effective for Atopic Eczema, ranking it as the top repurposing candidate with a prediction score of 99.96%. Currently 2 clinical trials and 20 publications have been identified in this direction, though the evidence is largely indirect — a critical contact-sensitization safety paradox must be resolved before clinical advancement.

Quick Overview

Item	Content
Original Indication	Asthma, COPD, Crohn's disease, microscopic colitis (established global uses; no Saudi Arabia registration on record)
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.96%
Evidence Level	L3
Saudi Arabia Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal mechanism of action data is not available in the current records. Based on information embedded in the evidence pack's mechanistic rationale and supporting literature, budesonide is a synthetic glucocorticoid receptor (GR) agonist. It activates the nuclear GR to suppress the TSLP/IL-33–driven Th2 immune axis, downregulating IL-4, IL-5, and IL-13, reducing eosinophilic infiltration of mucosal tissues, and blunting IgE-mediated inflammatory cascades. Its established efficacy across airway and gastrointestinal mucosal inflammation is built on this same mechanism.

Atopic eczema (atopic dermatitis) is characterized by Th2-dominant skin barrier dysfunction, eosinophil and mast cell infiltration, and elevated IgE — the exact immunological axis that budesonide targets in the airways and gut. The predicted repurposing therefore has a sound mechanistic basis. Importantly, topical corticosteroids are already a backbone of standard atopic dermatitis management globally, making this prediction an extension of a recognized pharmacological principle rather than a speculative leap.

The key limiting factor for budesonide specifically is dermal delivery: its physicochemical properties restrict skin penetration compared to conventional topical corticosteroids. A 2024 preclinical study (PMID 38275852) directly addressed this by formulating budesonide into pH-sensitive Eudragit L 100 nanoparticles embedded in a hydrogel, exploiting the characteristic acidic pH shift in atopic lesions to achieve targeted local release. This formulation innovation provides proof-of-concept that the delivery barrier is tractable, but clinical validation is entirely absent.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04680117	N/A	Unknown	150	Characterises endotypes of severe paediatric asthma (0–12 yr) using phenotypic, immunological, metabolomic and microbiota analyses; atopic comorbidity is included but budesonide treatment of eczema is not a study objective
NCT01028560	Phase 1/2	Completed	58	Allergy immunotherapy in atopic wheezing children (18 mo–3 yr) at high risk of asthma; eczema is an inclusion criterion but not a primary endpoint — budesonide would serve only as background therapy

Neither trial directly evaluates budesonide as a treatment for atopic eczema. No Grade A or B trials are available for this indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38275852	2024	Preclinical / Formulation	Gels (Basel)	Budesonide-loaded Eudragit L 100 nanoparticles in pH-sensitive hydrogel improve dermal penetration and targeted release at atopic lesion sites; provides formulation feasibility basis for topical AD therapy
9496795	1998	Clinical Study	Pediatric Dermatology	Knemometry in 14 children (5–12 yr) with AD using topical budesonide: measurable short-term lower-leg growth suppression observed, confirming clinically significant systemic absorption through inflamed skin
8864369	1996	Clinical Study	Dermatology (Basel)	Topical glucocorticosteroids in AD children suppressed IGF axis and reduced bone/collagen turnover markers; underscores systemic endocrine risk of topical budesonide in paediatric populations
21062310	2010	Veterinary RCT	J Vet Pharmacol Ther	Randomised, blinded, placebo-controlled crossover trial (29 dogs): 0.025% budesonide leave-on conditioner (Barazone) significantly reduced skin lesion scores and pruritus in canine AD, providing species-parallel efficacy signal
30053491	2018	Clinical Study	J Am Acad Dermatol	Allergic contact dermatitis to topical medications in 337 AD adults: budesonide identified as a sensitising allergen — skin barrier disruption in AD heightens contact sensitisation risk
35133669	2022	Cross-sectional Cohort	Contact Dermatitis	Asian dermatology centre: AD patients showed similar or higher positive patch-test rates versus non-AD; corticosteroid hypersensitivity including budesonide documented in this population
24603519	2014	Clinical Study	Dermatitis	Contact hypersensitivity to corticosteroid series in AD adolescents and adults: budesonide in European standard series elicited positive reactions, challenging its safe use in this patient group
33931866	2021	Registry / Epidemiology	Contact Dermatitis	Italian SIDAPA baseline series (2018–2019): budesonide is the European standard marker for corticosteroid hypersensitivity; a decreasing allergy trend observed over two decades, but sensitisation remains clinically relevant
37927648	2023	Case Report	Cureus	81-year-old with history of AD developed Type I hypersensitivity (facial angioedema, urticaria) to corticosteroids; illustrates rare but serious immediate hypersensitivity risk in atopic individuals
16925687	2006	Observational	Pediatr Allergy Immunol	Exhaled breath condensate pH in atopic children with asthma, rhinitis, and AD: confirms the atopic march — AD patients receiving background budesonide therapy tracked in same cohort, providing contextual safety data

Saudi Arabia Market Information

Budesonide is currently not registered in Saudi Arabia. No marketing authorisations were identified in the regulatory database query conducted on 2026-03-29. This means there is no locally approved label, no authorised indication text, and no Saudi-specific prescribing data available.

Safety Considerations

Key Safety Signal — Contact Sensitisation Paradox:

A recurring and clinically important finding across multiple independent studies is that budesonide can act as a contact allergen in the very patients it is intended to treat. Atopic dermatitis patients have compromised skin barriers and heavy exposure to topical medications, placing them at disproportionately elevated risk. Specific concerns:

Multiple studies (PMID 30053491, 35133669, 24603519, 33931866) document budesonide-induced allergic contact dermatitis in AD patients
Budesonide has been included in the European Baseline Patch Test Series since 2000 specifically because of this sensitisation potential
Topical budesonide in paediatric AD patients causes measurable HPA axis suppression and growth inhibition from percutaneous absorption through inflamed skin (PMID 9496795, 8864369)
A documented case of Type I hypersensitivity reaction (angioedema, urticaria) in an AD patient receiving corticosteroid therapy (PMID 37927648)

For full prescribing contraindications and warnings, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: Although budesonide's Th2-suppressing mechanism is directly relevant to atopic eczema pathophysiology, no clinical trials exist that evaluate it as an eczema treatment in humans, and a substantial contact-sensitisation safety signal — a pharmacological paradox where the drug may worsen the very condition it targets — must be systematically addressed before clinical advancement is justified.

To proceed, the following is needed:

Systematic evaluation of the contact-sensitisation paradox: prospective patch-testing to determine the prevalence of pre-existing budesonide hypersensitivity in the target AD patient population
Preclinical in vivo efficacy studies using novel delivery systems (e.g., pH-responsive nanoparticle hydrogels as described in PMID 38275852) to confirm therapeutic benefit outweighs sensitisation risk
Formal MOA documentation from DrugBank to support regulatory-grade mechanism review
HPA axis and growth monitoring protocol for paediatric subgroups
Comparative positioning against already-approved topical corticosteroids for AD (e.g., mometasone, triamcinolone) to justify a budesonide-specific development path
Saudi Arabia regulatory registration pathway assessment before any local clinical evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.